BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Given the structural headwinds in the U.S. faced by Indian generic companies, Sun Pharmaceutical Industries Ltd.’s investments to build a branded specialty business is a key differentiator.
However, specialty pharma is a vastly different business model compared to traditional generics, requiring significantly superior research and development skills, merger and acquisition capabilities, business development strategy and risk appetite.
Having built a branded portfolio focused on dermatology and ophthalmology, Sun Pharma is ahead of Indian peers in building a specialty business in the U.S.
Ramp-up of Ilumya, Cequa, Yonsa, Xelpros, Bromsite and Odomzo sales are drivers for Sun Pharma’s specialty business in the next three to four years.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR